Prelude Capital Management, LLC Bio Xcel Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.57 Billion
- Q3 2024
A detailed history of Prelude Capital Management, LLC transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 2,000 shares of BTAI stock, worth $5,960. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,000Holding current value
$5,960% of portfolio
0.01%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
51Shares Held
3.07MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$3.58 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$1.31 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$888,1680.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$551,4720.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$387,0090.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $83.5M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...